受强制性开放获取政策约束的文章 - Tony Ho了解详情
无法在其他位置公开访问的文章：2 篇
Antimigraine efficacy of telcagepant based on patient's historical triptan response
TW Ho, J Olesen, DW Dodick, J Kost, C Lines, MD Ferrari
Headache: The Journal of Head and Face Pain 51 (1), 64-72, 2011
强制性开放获取政策： US National Institutes of Health
Improving patient selection for clinical acute stroke trials
C Weimar, TW Ho, Z Katsarava, HC Diener
Cerebrovascular Diseases 21 (5-6), 386-392, 2006
强制性开放获取政策： German Research Foundation
可在其他位置公开访问的文章：12 篇
The Parkinson progression marker initiative (PPMI)
K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ...
Progress in neurobiology 95 (4), 629-635, 2011
强制性开放获取政策： US National Institutes of Health
Randomized, controlled trial of telcagepant for the acute treatment of migraine
KM Connor, RE Shapiro, HC Diener, S Lucas, J Kost, X Fan, K Fei, ...
Neurology 73 (12), 970-977, 2009
强制性开放获取政策： US National Institutes of Health, German Research Foundation
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
DJ Hewitt, SK Aurora, DW Dodick, PJ Goadsby, Y Ge, R Bachman, ...
Cephalalgia 31 (6), 712-722, 2011
强制性开放获取政策： US National Institutes of Health
Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial …
JM Lee, A Cimino-Mathews, CJ Peer, A Zimmer, S Lipkowitz, ...
Journal of Clinical Oncology 35 (19), 2193-2202, 2017
强制性开放获取政策： US National Institutes of Health
Outcomes and endpoints in cancer trials: bridging the divide
MK Wilson, D Collyar, DT Chingos, M Friedlander, TW Ho, K Karakasis, ...
The lancet oncology 16 (1), e43-e52, 2015
强制性开放获取政策： Cancer Research UK, UK Medical Research Council
Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned
RA Hauser, F Stocchi, O Rascol, SB Huyck, R Capece, TW Ho, P Sklar, ...
JAMA neurology 72 (12), 1491-1500, 2015
强制性开放获取政策： National Institute of Health and Medical Research, France, Parkinson's …
Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension
A Chabi, R Varma, JC Tsai, R Lupinacci, J Pigeon, C Baranak, L Noble, ...
American journal of ophthalmology 153 (6), 1187-1196, 2012
强制性开放获取政策： US National Institutes of Health
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
F Stocchi, O Rascol, RA Hauser, S Huyck, A Tzontcheva, R Capece, ...
Neurology 88 (23), 2198-2206, 2017
强制性开放获取政策： National Institute of Health and Medical Research, France, Parkinson's …
Long‐term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
SA Factor, K Wolski, DM Togasaki, S Huyck, M Cantillon, TW Ho, ...
Movement Disorders 28 (6), 817-820, 2013
强制性开放获取政策： US National Institutes of Health, Government of Spain
Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor …
DW Dodick, J Kost, C Assaid, C Lines, TW Ho
Cephalalgia 31 (3), 296-300, 2011
强制性开放获取政策： US National Institutes of Health
High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infection
DT Claiborne, Z Detwiler, SS Docken, TD Borland, D Cromer, ...
Nature Communications 16 (1), 446, 2025
强制性开放获取政策： National Health and Medical Research Council, Australia
Migraine and olcegepant–Authors' reply
TW Ho, MD Ferrari, DW Dodick, J Kost, P Winner
The Lancet 373 (9668), 1003-1004, 2009
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定